ClinicalTrials.gg
RecruitingNCT06521255Updated Jul 25, 2024

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of Tafasitamab and Lenalidomide in DLBCL, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom

02

Conditions studied

  • DLBCL
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 Years and older.
  2. One of the histologies of DLBCL confirmed by participated sites below with,not otherwise specified;T-cell/histiocyte-rich large B-cell lymphoma;Epstein-Barr virus (EBV) positive DLBCL (EBV-positive DLBCL); Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse; Disease transformed from an earlier diagnosis of low-grade lymphoma into DLBCL with DLBCL treatment failure.
  3. Availability of tumor tissue biopsied post last and prior to current study treatment for the patients enrolled in safety and tolerability stage.
  4. (R/R) DLBCL, at least one (≥1) but no more than three (≤3) line of prior systemic therapies.
  5. Patients who have not received high dose therapy/stem cell transplantation (HDT/SCT) must be ineligible for HDT/SCT.
  6. At least one measurable site of disease per CT or magnetic resonance imaging (the longest axis of the lymph node lesion is > 1.5 cm, and the longest diameter of the extra-nodal lesion is > 1.0 cm).
  7. PS score of 0 to 2.
  8. Subject must have adequate organ functions, and the laboratory values comply with the protocol requirements.
  9. of ≥ 3 months.
  10. before screening and can understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Existing or prior history of other malignant tumor within 3 years, except for those who have received curative treatment.
  2. Current or history of central nervous system (CNS) lymphoma.
  3. Known high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
  4. Primary mediastinal B-cell lymphoma.
  5. History of stem-cell transplantation.
  6. Prior exposure to anti-CD19 treatment, and (or) failed with gemcitabine plus platinum-based agent combination therapy.
  7. Current toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, neutrophil, and ).
  8. cardiovascular disease or nervous system disease.
  9. History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period.
  10. Uncontrolled systemic infection requiring parenteral intravenous anti-infective therapy.
  11. Known (HIV), or serologic status reflecting active or C infection.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (estimated)

Study arms

  • Experimental
    Tafasitamab and lenalidomide in combination with gemcitabine and oxaliplatin

    Drug: Tafasitamab · Drug: Lenalidomide · Drug: Gemcitabine · Drug: Oxaliplatin

  • Active comparator
    Rituximab in combination with gemcitabine and oxaliplatin

    Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity(DLT)and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0

    Time frame: within 28 days after therapy initiation

  2. PFS assessed by IRC according to Lugano 2014

    Time frame: 1-3 years approximately

Secondary outcomes

  1. Objective Response Rate (ORR) according to investigator.

    Time frame: 1-3 years approximately

  2. Complete Response Rate (CRR) according to investigator.

    Time frame: 1-3 years approximately

  3. Duration of Response (DOR) according to investigator.

    Time frame: 1-3 years approximately

  4. Progression free survival (PFS) assessed by investigator according to the Lugano 2014

    Time frame: 1-3 years approximately

  5. Time to response (TTR)

    Time frame: 1-3 years approximately

  6. Overall Survival (OS)

    Time frame: 1-3 years approximately

  7. Time to next treatment (TTNT)

    Time frame: 1-3 years approximately

  8. Adverse events assessed by CTCAE version 5.0 criteria.

    Time frame: 1-3 years approximately

  9. Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)

    Time frame: 1-3 years approximately

  10. Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on EuroQol five dimensions questionnaire (EQ-5D-5L)

    Time frame: 1-3 years approximately

07

Study locations

3 of 20 sites recruiting
  • Beijing Hospital
    Beijing, China
    Not yet recruiting
    • Hui Liu · Contact
  • The First Hospital Of Jilin University
    Changchun, China
    Not yet recruiting
    • Ou Bai · Contact
  • Hunan Cancer Hospital
    Changsha, China
    Not yet recruiting
    • Yajun Li · Contact
  • Chenzhou No.1 People's Hospital
    Chaozhou, China
    Not yet recruiting
    • Xinquan Liang · Contact
  • Sichuan Province People's Hospital
    Chengdu, China
    Recruiting
    • Rong Xiao · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Not yet recruiting
    • Hongbin Zhang · Contact
  • Guangdong General Hospital
    Guangzhou, China
    Not yet recruiting
    • Wenyu Li · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
    Recruiting
    • Qingqing Cai · Contact
  • Hangzhou First People's Hospital
    Hangzhou, China
    Not yet recruiting
    • Xiangmin Tong · Contact
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, China
    Not yet recruiting
    • Wenjuan Yu · Contact
  • Shandong Cancer Hospital and Institute
    Jinan, China
    Not yet recruiting
    • Zengjun Li · Contact
  • Jiangxi Cancer Hospital
    Nanchang, China
    Not yet recruiting
    • Yan Huang · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanjing, China
    Not yet recruiting
    • Fei Li · Contact
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, China
    Not yet recruiting
    • Weili Zhao · Contact
  • The Second Affiliated Hospital of Soochow University
    Suzhou, China
    Recruiting
    • Bingzong Li · Contact
  • Tianjin First Central Hospital
    Tianjin, China
    Not yet recruiting
    • Qi Deng · Contact
  • Xinjiang Medical University Affiliated Cancer Hospital
    Urumqi, China
    Not yet recruiting
    • Shujuan Wen · Contact
  • The First Affiliated Hospital Wenzhou Medical University
    Wenzhou, China
    Not yet recruiting
    • Songfu Jiang · Contact
  • Union Hospital Tongji Medical College
    Wuhan, China
    Not yet recruiting
    • Liling Zhang · Contact
  • Henan Cancer Hospital
    Zhengzhou, China
    Not yet recruiting
    • Keshu Zhou · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Sep 2028, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 25, 2024
StartActual
May 7, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Dec 2029
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06521255
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
May 7, 2024
Primary completion
Sep 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 25, 2024

Study contacts

Weili Zhao
Contact
zwl_trial@163.com
+86 021-64370045

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tafasitamab · Lenalidomide

Start the discussion